- Overview
- Bayer Group
- Stock
- Debt
- Reports
- Annual Stockholders’ Meeting 2020
- Events
- Inside Information
- Latest Inside Information
- Archive Overview
- Inside Information 2019
- Inside Information 2018
- Inside Information 2017
- Ad-hoc 2016
- Ad-hoc 2015
- Ad-hoc 2014
- Ad-hoc 2013
- Ad-hoc 2012
- Ad-hoc 2011
- Ad-hoc 2010
- Ad-hoc 2009
- Ad-hoc 2008
- Ad-hoc 2007
- Ad-hoc 2006
- Ad-hoc 2005
- Ad-hoc 2004
- Ad-hoc 2003
- Ad-hoc 2002
- Ad-hoc 2001
- Ad-hoc 2000
- Ad-hoc 1999
- Ad-hoc 1998
- News
- Investor News
- Press
- Archive
- Overview
- Investor News 2019
- Investor News 2018
- Investor News 2017
- Investor News 2016
- Investor News 2015
- Investor News 2014
- Investor News 2013
- Investor News 2012
- Investor News 2011
- Investor News 2010
- Investor News 2009
- Investor News 2008
- Investor News 2007
- Investor News 2006
- Investor News 2005
- Investor News 2004
- Investor News 2003
- Investor News 2002
- Investor News 2001
- Investor News 2000
- Handouts
- Downloads
- Service
Data for Rivaroxaban presented at the 9th EFORT Congress
May 29 - June 1, 2008
Nice, France
Rivaroxaban data from the RECORD4 clinical trial have been presented at the annual meeting of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT).
Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2 and 3 / U.S. Submission Planned for mid 2008 / Prof. Turpie: "Rivaroxaban has the potential to revolutionize the way we prevent the formation of dangerous blood clots" more
Friday, May 30, 2008 at 05:30 p.m. CEST (3:30 p.m. GMT):
Investor Conference Call - Review of Rivaroxaban Data at EFORT Congress
with
Alexander G.G. Turpie, M.D., Chair of the steering committee and lead investigator RECORD4 study
Dr. Kemal Malik, Head of Global Development at Bayer Schering
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations
| Background Information | |
|---|---|
| About Rivaroxaban | Download PDF collect (79 KB) |
| About RECORD Studies | Download PDF collect (61 KB) |
| About Rivaroxaban Clinical Studies | Download PDF collect (68 KB) |
| History Of Anticoagulants | Download PDF collect (350 KB) |
| Understanding Venous Blood Clots | Download PDF collect (51 KB) |
| Glossary | Download PDF collect (38 KB) |
Prevention of venous thromboembolism with rivaroxaban after total hip replacement: economic impact of extended thromboprophylaxis
Rivaroxaban for prevention of venous thromboembolism after total hip replacement: impact on healthcare costs based on the RECORD1 study
Rivaroxaban for thromboprophylaxis after total knee replacement: the RECORD3 trial
Comparison of rivaroxaban – an oral, direct Factor Xa inhibitor – and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase III study)
Comparison of oral rivaroxaban and subcutaneous enoxaparin for extended thromboprophylaxis following total hip replacement: RECORD1
An evaluation of the efficacy and safety of extended thromboprophylaxis with oral rivaroxaban compared with short-term subcutaneous enoxaparin following total hip replacement (RECORD2: a phase III study)